Acuta Capital Partners, LLC Anavex Life Sciences Corp. Transaction History
Acuta Capital Partners, LLC
- $98.8 Million
- Q3 2024
A detailed history of Acuta Capital Partners, LLC transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Acuta Capital Partners, LLC holds 1,000 shares of AVXL stock, worth $11,230. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,000Holding current value
$11,230% of portfolio
0.01%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding AVXL
# of Institutions
157Shares Held
27.4MCall Options Held
515KPut Options Held
838K-
Black Rock Inc. New York, NY6.39MShares$71.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.74MShares$53.2 Million0.0% of portfolio
-
State Street Corp Boston, MA3.07MShares$34.4 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.88MShares$21.1 Million0.0% of portfolio
-
Nwam LLC Mercer Island, WA910KShares$10.2 Million0.32% of portfolio
About ANAVEX LIFE SCIENCES CORP.
- Ticker AVXL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,942,800
- Market Cap $875M
- Description
- Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...